Afriag Share Discussion Threads

[pr100] 27/9/2019 14:58

I feel so sorry or John Peterson and his £18k loss on Afriag. He seems a thoroughly decent, honest and patient chap who deserved better. He hardly complains about it, acknowledging that much of the responsibility for his loss rests on his own shoulders.

But all he did was believe the BS spouted by David Lenigas in "regulated" announcements. We are supposed to be able to believe these announcements and he won't be alone in swallowing the nonsense therein. The system is broken: regulators don't check deeply enough to be able to warrant the accuracy of RNS's. And the job of conducting due diligence as a private individual is never easy - especially when shareholders funds are allegedly invested in private companies in remote jurisdictions.

Lenigas won't care about John. The roads to ruin are littered with the detritus of other Lenigas followers - in Afriag and dozens more confected companies. There has only ever been one winner in the Lenigas game.

But on the other hand, there have been warnings a-plenty about Afriag - from me and others. If John dismissed them because others told him I had to have a vested interest in Afriag's demise, that's his own fault. The desire to bury your head in the sand if you are a Lenigas investor is understandable initially; but after a sustained period of value destruction and blatant lies, most of the followers see the light and bail out. John stayed too long and it cost him dearly.

The only way to evaluate Lenigas RNS's is to assume from the get-go that they are a pack of lies which require you to prove the veracity of the outrageous claims therein before parting with any of your kids' inheritance. On this basis, Lenigas would have had zero investors and a huge body of PIs would be much wealthier today.

This latest Apollon blag is just more of the same. Anyone who swallows it must seek help from others with more experience or more wisdom. Afriag is doomed. Salvage what you can.

[cpap man] 26/9/2019 08:10

26 September 2019
AfriAg Global PLC
(“AfriAg Global”, the “Group” or the “Company”;)

Unaudited Interim Results for the six months to 30 June 2019

AfriAg Global PLC (NEX: AFRI), today announces its interim results for the 6-month period ended 30 June 2019.

Investment policy change to include Medical Cannabis investments:

On 12 September 2018, shareholder approval was obtained at a general meeting for the expansion of the Company’s investment strategy to include medicinal cannabis. The Company has now expanded its existing investment strategy to also include investments in companies, projects or products that are progressing research in and development of medicinal cannabis and its derivatives, producing or cultivating medicinal cannabis, producing or supplying products derived from or related to cannabis (including, but not limited to, hemp and cannabidiol products); and/or commercialising or marketing medicinal cannabis and its derivatives. The Company sees tremendous opportunities in the sector.

The Company has already made a number of investments into this medical cannabis sector and going forward, the Company is likely to increase its exposure in this sector by looking to acquire control of certain target companies, although it may also consider acquiring non-controlling shareholdings in legal medical cannabis companies.

Future investments to be considered by the Company may be in either quoted or unquoted securities and may be made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects and these investments can be at any stage of development. Accordingly, the Company’s proposed future equity interests in proposed investments may range from a minority position all the way up to 100 percent ownership. The Directors primary objective is to achieve the best possible value over time for Shareholders, primarily through capital growth.

The Company’s Medical Cannabis Investments:

During the period the Company announced it had agreed with Apollon Formularies Ltd (“AFL” or “Investee̶1;) a UK incorporated company, to: (1) subscribe for 1.2 million shares in AFL at a price per share of £0.25 representing approximately 0.71 per cent. of AFL’s issued share capital for an aggregate investment amount of £300,000; and (2) subscribe for 2.8 million shares at a price per share of £0.25 representing approximately 1.63 per cent. of AFL’s issued share capital for an aggregate investment amount of £700,000, which investment was approved by shareholders at the General Meeting on 19 June 2019 (the “Investments”).

The Company raised £1.25m during the period to assist with the acquisition of this Investment and now owns a total of 4.0 million shares in AFL, representing circa 2.325 per cent. of AFL’s issued share capital.

The Company is working diligently with its legal advisors on the complicated and necessary due diligence to potentially acquire all of AFL. Further announcements will be made with respect to this as legal and accounting work progresses. As previously announced to shareholders, the Company is in detailed discussions and negotiations with the major shareholders of AFL, with which it has been granted a right of first refusal to acquire all the issued and outstanding shares owned by those shareholders in consideration for the issue and allotment to those shareholders of new ordinary shares in the capital of the Company at a price of 0.1 pence per new ordinary share (“ Right of First Refusal ”) which values the transaction at circa £40,000,000.

Following exercise of the Right of First Refusal, which will be subject to approvals from (as applicable) (1) all the necessary government authorities, including the Cannabis Licencing Authority (in Jamaica ); (2) all necessary regulatory authorities; (3) the necessary approvals from the Company’s shareholders; and (4) approvals from the shareholders of AFL, the existing shareholders of AFL will hold circa 93.54 per cent. of the issued share capital of the Company. Following completion of the Investments and should the Company exercise the Right of First Refusal, the resulting enlarged group will be a vertically integrated medicinal cannabis group with operations in Jamaica and with plans to expand elsewhere throughout the world.

Agriculture Investments:

Sadly, the market has not considered what has been achieved with our investments in the agricultural sector well, even though these investments continue to perform in a difficult global environment. We, as a Company, will assess whether further or continued investment in the sector is warranted, as we move towards the medical cannabis focus. To this extent, the Company has decided that no further investment will be made in to our current agri-logistics investments as we now move our investment focus to the legal medical cannabis sector.

Financial Results:

During the period, the Company generated revenues to £1,323,000 (6 months ended 30 June 2018: £1,501,000) and made a gross profit of £163,000 (6 months ended 30 June 2018: £38,000). The operating loss for the period was £30,000 (6 months ended 30 June 2018: loss £118,000). Loss before tax was £867,000 (6 months ended 30 June 2018: loss £97,000) mainly attributable to the impairment of associate of £850,000.

There was a weighted loss per share of 0.047p (30 June 2018: loss per share 0.007p).

The unaudited interim results to 30 June 2019 have not been reviewed by the Company’s auditor.

In Conclusion:

We have a very unique ability, being one of the few companies listed in London and indeed Europe, to actually undertake investments in the fast-growing legal medical cannabis sector. It has taken a great deal of management and legal work to achieve this, and this will be a big focus for the management over the coming year. Having recently completed our initial investment in Apollon Formularies Ltd, we are actively pursuing to further increase our stake in this key investment further as discussed above. We fully appreciate that time is of the essence, and your board, its lawyers and indeed the AFL team are working tirelessly to wrap up this transaction as soon as possible.

The Board would like to take this opportunity to thank our shareholders, staff and consultants for their continued support and I look forward to reporting further significant progress over the next period and beyond.

The directors of the Company accept responsibility for the contents of this announcement.

David Lenigas
Executive Chairman
26 September 2019

For further information, please contact:

AfriAg Global plc: [phone]
David Lenigas

Corporate Adviser and Broker:
Peterhouse Capital Limited [phone]
Guy Miller / Allie Feuerlein

[pr100] 19/9/2019 09:44

In Lenigas's bank maybe. Shareholders in his listed companies tend to have no money in their bank. He just left GNAL after a 7-month spell on the board during which period the share price fell from 7c to 0.03c. PIs who keep losing 96% of their money tend not to have much in the bank.

[apfindley] 19/9/2019 09:01

Marvellous lol. But does it put f-ing dollars in the bank?

[pr100] 17/8/2019 09:09

AfriAg PLC and Pty, including Lenigas and notorious tobacco smugglers Paul de Robillard and Yusuf Kajee, charged with attempted state capture in Lesotho in bid to rubber-stamp cannabis deals.

[pr100] 21/7/2019 07:44

"Apollon seem to have published some photos to allay my concerns about their facilities. Unfortunately, they show a tiny glasshouse with a handful of plants and no irrigation or growing infrastructure - and a "laboratory that obviously isn't a laboratory.




Well, these two photos now seem to have been removed from the slideshow on the Doc's Place home page - together with all references to cannabis. It is now apparently just a B&B with a massage parlour.

If the business plan has changed, surely investors should be told?

[pr100] 21/7/2019 07:29

"8. Any credible peer-reviewed proof anywhere in the world that cannabis is an effective treatment for the following diseases and illnesses that AFJ claims to be able to treat with it: Prostate Cancer; Breast Cancer; Brain Cancer; Chronic Pain; Arthritis; Crohn’s Disease/Ulcerative Colitis; Glaucoma; HIV; Alzheimer’s; Lupus (SLE); Parkinson’s disease."

So the above list of miracle cures has just been removed from the Apollon/Doc's Place website - which doesn't even mention cannabis any more.

Now seems to be promoted as just a Bed & Breakfast - without any cannabis therapies - with Barnhill Jnr acting as the customer.

This may be a step toward Legal, Decent, Honest & Truthful but it isn't the story Afriag PIs/investors were spun.

[pr100] 19/7/2019 18:00

Drone view of Doc's Place, Negril. No way of accommodating 100 paying guests here - even if they get permission to test unlicensed cannabis cures on them... Wonder if they will tell guests that they are being used as unpaid guinea pigs?

[pr100] 19/7/2019 07:14

Not sure how it works in Jamaica but in most parts of the world you wouldn't be allowed to prescribe or administer cannabis (or any) treatment for medical conditions unless it has been proven effective and licensed by the medical authorities. And the notion that you could get away with branding a product "Apollon Cancer" is fanciful and wrong.

Apollon's long list of diseases and conditions which it offers cannabis treatment for includes only one - epilepsy - for which cannabis is an approved medication and that license is held exclusively by Sativex.

It's hard to imagine that Jamaica would flaunt the WHO rules and allow Apollon to operate in this maverick way. The story may work for mug punters who don't do any DD but it's dead in the water. Save your money.

[longrod] 17/7/2019 17:34

Looking towards the future and not the past which I understand is fraught with a lot of historical financial pain I along with many other UK and international Investors have been quietly supporting some very unique research into various medical formulations for human ailments. The company has already identified 10 such formulations which it has trade marked and is producing at its licensed processing facility including "Apollon Cancer" "Apollon Seizure" etc etc

The company has a team of globally recognised physicians, oncologists, one brain surgeon, a homeopathic specialist and clinical pathologists that have worked together for decades. Dr. Barnhill invented machine vector learning a subject cited in more than 10,000 international peer reviewed medical and scientific publications and he and his team have previously identified, patented and subsequently sold to big Pharma treatments for melanoma, breast and prostate cancer.

Its worth actually waiting for this. But if you decide not to it is of no matter because if you sell at these prices you sell to people who know and understand.

I will most likely attract some initial criticism from some old afriag shareholders as they need somewhere to vent but as i said, this is about the future, not the past.

Happy to discuss with sensible people.

[longrod] 17/7/2019 17:11

Undertaking a transaction in medical cannabis which if successful will create the first vertically integrated medical cannabis company to be listed in the UK. Apollon will also be the first true medcan company in all of Europe with a first class medical team managing medical trials designed to deliver patented formulations for the mass market.

[pr100] 17/7/2019 09:06

Longrod, you're a card. If you have seen these things for yourself, post some photos. Surely there's nothing secret about showing off the facilities?

And please link me to Dr Barnhill's published cannabis research and current patents.

These are the basic things you should be showing to potential new investors to prove that it's not all smoke and mirrors.

[longrod] 17/7/2019 07:32

pR100

You just don't get it, I'm coming from the Apollon side.

I have seen everything you mention above as have all Apollon shareholders. That's why we have invested millions to date. Your claim this is all smoke and mirror just shows how ill informed you are. I Don't Care about your little afriag misadventures. All we care about is that its a shell and we are about to take it over, the fact that it is a crashed car is why it's both available and desirable for us . Clearly you are not experienced at these things. You keep saying afriag is done for. I agree, that's why we are taking it over. You obviously do not understand turnarounds, well my friend I do. Done lots of them, they have all worked and worked well. See I reckon you don't even own shares in afriag you are just a sad and bitter Mr anonymous with nothing better to do than get it wrong. Seen types like you before axe to grind won't accept reality it makes me laugh, It makes me laugh a lot actually to think about you and your positions on this. You just don't get it and worse seem incapable of realising change is upon you and keep banging the afriag drum

Anyway you know what say about arguing with idiots. Lets just see what happens. But £1m in and 85m shares traded yesterday tells me that this is going exactly according to plan regardless of what you think little man and I bet you (a lot of money in Apollon 😂😂) that you are wrong.

Also thanks for reminding me, I forgot to filter you a few days ago.

[pr100] 16/7/2019 11:45

Longrod, all potential investors should be shown *proof* that a company is worth investing in. Otherwise, it's like buying fluffy bears from a street market. You seem to place a lot of faith in the due diligence conducted by NEX and Afriag's lawyers - but they just don't dig that deep. They take on trust what they are told about the associate companies of proposed investees - especially if they are privately owned. So do auditors.

So far, we have been told a load of hogwash about Apollon UK and Apollon Jamaica because none of it is verifiable.

What we do know is that Doc's Place opened two branches in Jamaica in 2016/7 both of which closed down a year or two later.

And we know that Dr Barnhill's global reputation is based on AI, not on medical cannabis. And that the patents he has filed over the years are owned by his former employers.

And we know that, other than RNSs issued by Afriag, there has been precious little written about Apollon Jamaica and its pioneering work. If you ignore the advertorials in a strange magazine called Edibles, virtually nothing. And we know that they still aren't taking any bookings for this fantastic revival in Negril (none of which has been covered in the local media).

Too much smoke and mirrors and not enough substance to make this a serious proposition so be careful with your cash.

[longrod] 16/7/2019 10:42

Firstly these documents haven't been released so clearly i would be unable to provide them. But more importantly your refusal to accept what happening globally is what derails you argument PR100. Obviously the NEX regulator would have reviewed these claims along with the various legal teams.

This is whats so amusing with these chat boards.

Everyone can be an "anonymous expert"

You can deny the trend as much as you like however this is truly a global phenomenon.

Constellation investing 5bn
Marlboro tobacco investing billions
Market caps in the billions
Global decriminalisation is occurring along with loosening of medical cannabis legislation all over the world. The US is next. You look stupid to say otherwise but hey, whatever floats you boat.

You are clearly bitter
Its clearly personal
Afriag is a shell
This is a new emerging business and will be the first full spectrum medical cannabis company listed in london, not just a CBD wannabe!!

Dr Barnhill is globally recognised as a leading expert in the space. There is a team of medical professionals surrounding him that make you look like a dancing singing clown

I think you are missing the point here completely as you are so fixated on Lenigas.

Lets see what the merger documents say when they are released in due course.

I don't have them for you I'm sorry and i just have to put you on filter as you are just taking up time on nonsense to me. I don't care about Lenigas, this is about the future not the past.

Also i note lots of little trades being sold into large single buy orders, always a good sign. 😉

As sam aftal said stay there and keep doing that, wont affect the outcome.

Where ohh where art thou sammy aftal??

[pr100] 16/7/2019 10:06

Longrod, you could say that my scepticism is personal. I am sceptical about everything David Lenigas touches (even though I have never been an investor, thank god). But if you are better informed than me, please set my mind at rest. Any of the following would be most welcome:

1. Any evidence, apart from a vague personal agreement, that Apollon Formularies Ltd (AFL) owns 49% of Apollon Formularies Jamaica (AFJ) and is entitled to receive 95% of its net profit (should it ever make any).

2. Any evidence, including photographs, that AFJ owns a cannabis laboratory and a cannabis cultivation greenhouse, as claimed.

3. Any evidence that AFJ owns any current patents.

4. Any evidence, including recent photographs, that Doc's Place Negril is up and running and open for business.

5. Any evidence that AFJ has an equity stake in Doc's Place Negril or is anything more than a franchise holder in a business which seemingly closed down a year ago.


6. Any evidence that AFJ has conducted scientific research and/or credible patient trials to prove the efficacy of its medical cannabis treatments.

7. Any evidence that AFJ has published peer reviewed scientific papers demonstrating the effectiveness of its cannabis treatments.

8. Any credible peer-reviewed proof anywhere in the world that cannabis is an effective treatment for the following diseases and illnesses that AFJ claims to be able to treat with it: Prostate Cancer; Breast Cancer; Brain Cancer; Chronic Pain; Arthritis; Crohn’s Disease/Ulcerative Colitis; Glaucoma; HIV; Alzheimer’s; Lupus (SLE); Parkinson’s disease.

9. Any evidence, other than the price Afriag paid for its shares, that AFL is worth £40m, or even £1m.

10. Any evidence that any David Lenigas public company has ever generated any value for its shareholders beyond brief P&D share price spikes - or that one has ever made a good investment on behalf of its shareholders.

Thanks for your help.

[longrod] 16/7/2019 09:58

Another home run!

PR100

Where are you now with your verbal diarrhoea and chronic depression.

This thing is getting traction seems to me.

[cpap man] 16/7/2019 07:15

NEX:AFRI



Tuesday 16 July, 2019
AfriAg Global Plc
Apollon Update: Production of Medical Cannabis Oils
16 July 2019

AfriAg Global PLC
(‘AfriAg’; or the ‘Company’;)

First production of licensed legal medical cannabis oils for commercial sale in Jamaica by Apollon Formularies Jamaica Ltd (“Apollon̶1;) completed.

Apollon, with its new State-of-the-Art Licensed Processing Facility in operation, will now focus on using its medical cannabis oil to produce medical cannabis products and pharmaceuticals for retail sales.

AfriAg Global PLC, a company whose shares are admitted to trading on London’s NEX Exchange, is pleased to announce that it has been advised by Apollon Formularies Ltd that Apollon has now completed its first production of licensed medical cannabis oils at its processing facility in Negril, Jamaica. These oils are the primary ingredient for medical cannabis-based pharmaceuticals, nutraceuticals, cosmeceuticals, and beverages. Apollon is continuing to progress rapidly towards producing products for retail sale in its Jamaican Cannabis Licensing Authority (“CLA”) Retail (Therapeutic Services) Licensed dispensary.

Highlights

Apollon’s State-of-the-Art Processing Lab is capable of producing large commercial amounts of medical cannabis oils and extracts. Extraction of medical oils has now begun, with efforts now focused upon the production of the first medical cannabis products to be available for use and sale in the company’s CLA Retail (Therapeutic Services) Licensed dispensary located on the premises of the Doc’s Place Wellness Resort in Negril, Jamaica.
Apollon medical service staff has been extended to include Dr. Marjorie Vassell and Dr. Alfred Dawes.
Apollon Cannabis Collective has been established. This collective is a commercial platform to facilitate and engage local farmers to grow medical cannabis crop for processing by Apollon at its licensed facilities, giving Apollon access to additional growers and land and reinforcing Apollon’s commitment to working with Jamaican farmers and businesses.
Continued work is underway by Apollon towards Tier 3 cultivation licence approval.
David Lenigas, AfriAg’s Chairman, commented:

“Apollon is developing its fully vertically integrated medical cannabis business in Jamaica at speed, and we welcome the news of its first successful production of medical cannabis oil. The availability and sale of these oils will facilitate production by Apollon of medical cannabis-based pharmaceuticals, nutraceuticals, and cosmeceuticals at its State-of-the-Art Processing Facility in Negril, Jamaica and provide cash flow that will be used to accelerate Apollon’s operational and expansion plans, which include: (i) pursuit of CLA Tier 3 cultivation license approval, and (ii) the completion and distribution of products for sale at Apollon’s fully licensed dispensary. Imminent revenue generation is a significant milestone for the business.”

[longrod] 15/7/2019 16:27

Sammy aftal give us an update pls

Seems there was no problems raising serious money for this.

Be good to get your views. Maybe cheer PR100 up from his deep depression.

🙂